drugset / Trial / NCT04848116
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Phase 2
Active not recruiting
24 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to assess safety and feasibility of pre-operative nivolumab in combination with BMS-986253 (anti-interleukin-8) in patients with squamous cell carcinoma of head and neck (SCCHN) who will undergo surgery.
Timeline
- Start
- 2021-04-24
- Primary completion
- 2027-04
- Completion
- 2030-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADAKITUG | Monoclonal antibody | 2400 mg | Intravenous |
| Subject | ADAKITUG | Monoclonal antibody | 3600 mg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |